Table 3 In-hospital mortality among patients with T1DM who underwent minor or major non-traumatic lower extremity amputations

Age groups (Years)^a,b,

18–49

11 (0.81)

31 (6.65)

50–59

10 (0.92)

24 (6.15)

60–69

10 (1.27)

31 (7.95)

70–79

17 (3.13)

48 (10.15)

80 + 

15 (6.91)

39 (13)

Sex ^a,b

Male

41 (1.36)

102 (7.59)

Female

22 (2.28)

71 (10.52)

Charlson Comorbidity Index Median (IQR)^a,b

Dead

2 (1)

2 (1)

Alive

1 (1)

1 (1)

Peripheral arterial disease, n (%)^a,b

No

13 (0.93)

27 (6.07)

Yes

50 (1.92)

146 (9.28)

Infection, n (%)

No

47 (1.54)

143 (8.47)

Yes

16 (1.70)

30 (9.09)

Peripheral neuropathy, n (%)

No

48 (1.49)

145 (8.47)

Yes

15 (1.93)

28 (9.1)

Ischemic Heart Disease, n (%)^a,b

No

48 (1.27)

137 (7.52)

Yes

15 (7.35)

36 (18.18)

Chronic Kidney Disease, n (%)^a,b

No

35 (1.14)

114 (7.59)

Yes

28 (3.06)

59 (11.41)

Hypertension, n (%)

No

49 (1.81)

121 (8.93)

Yes

14 (1.09)

52 (7.83)

Stroke, n (%)^b

No

60 (1.55)

151 (8.17)

Yes

3 (2.36)

22 (12.94)

Heart failure, n (%)^a

No

43 (1.22)

136 (8.15)

Yes

20 (4.23)

37 (10.57)

Lipid metabolism disorders, n (%)

No

53 (1.68)

147 (8.83)

Yes

10 (1.19)

26 (7.32)

Liver disease, n (%)

No

59 (1.53)

163 (8.38)

Yes

4 (2.74)

10 (13.33)

Dementia, n (%) ^b

No

63 (1.58)

159 (8.15)

Yes

0 (0)

14 (20.9)

Chronic pulmonary disease, n (%)

No

59 (1.56)

154 (8.23)

Yes

4 (1.98)

19 (12.84)

Connective tissue disorder, n (%)

No

62 (1.57)

172 (8.54)

Yes

1 (3.85)

1 (16.67)

Peptic ulcer, n (%)

No

63 (1.59)

169 (8.47)

Yes

0 (0)

4 (17.39)

Cancer, Metastatic cancer

No

62 (1.56)

171(8.58)

Yes

1 (3.57)

2 (7.69)

Human immunodeficiency virus, n (%)

No

63 (1.58)

173 (8.59)

Yes

0 (0)

0 (0)

Year^b

2001–03

18 (2.18)

58 (9.54)

2004–06

14 (2.26)

29 (7.71)

2007–09

8 (1.46)

26 (9.22)

2010–12

5 (0.87)

22 (8.87)

2013–15

7 (1.1)

16 (6.96)

2017–19

11 (1.39)

22 (8)